Rahul Sharma (Editor)

Anil Suri

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit

Anil suri zee news


Dr Anil Suri is an eminent cancer researcher working in the field of Translational Cancer research at National Institute of Immunology, New Delhi, India. He is an elected Fellow of National Academy of Medical Sciences (India), elected Fellow of National Academy of Sciences, India, editorial board member of Cancer Research (journal), elected Executive Member of Indian Association of Cancer Research (IACR), India (2016) and the Vice President of ISSRF.

Contents

Anil has been a visiting Professor at Mount Sinai Medical Center, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, National Cancer Institute, Georgetown University Medical Center (Lombardi Comprehensive Cancer Centre), Washington DC, Queen’s University Belfast, UK.

Anil suri naredco event speech


Human Cervical Cancer Trials in Stage IIIb cancer patients

He has discovered SPAG9, a novel cancer antigen that is expressed in reproductive tract, breast and various other malignancies. Human clinical trials employing recombinant SPAG9 have been initiated in Cervical Cancer patients using Dendritic Cell based vaccine at Adyar Cancer Institute (WIA), Chennai entitled “Cancer immunotherapy dendritic cell vaccine based immunotherapy in cervical cancer-A phase II, double blind, randomized, three arm study to evaluate the efficacy of dendritic cell vaccine in stage IIIB cervical cancer” (n=54 patients)” Protocol No. CI/MOL ONC/DC VACCINE Version 5.0.

Clinical Relevance

He is involved in Cancer Research Program that is aimed to identify leads for early detection and diagnosis, treatments and cure. This important aspect of Cancer Research Program involves Biomarker discovery for early detection and diagnosis and Cancer Immunotherapy.The cancer biomarker candidates discovered by Dr Suri in various cancers of Breast, Ovarian, Cervical, Renal cell carcinoma, Thyroid, Bladder, Colon as well as leukemia all of which have been published in prestigious International Cancer Journals.

Patents

  1. Suri A (2013) siRNA useful in inhibiting cellular growth/proliferation of cancerous tissues. India Patent No.257434 (Granted on October 1, 2013)
  2. Suri A (2012) Nucleotide sequences: Inhibition of SPAG9 expression with SiRNAs. Country: United States of America Patent No. US 8227591 (Filed on Aug 8, 2007, Granted on July 24, 2012)
  3. Suri A (2012) Novel Cancer Associated antibodies & antigens and their use in cancer diagnosis. Europe Patent No EP 1796723 (Filed on Sept 4, 2007, Granted on Oct 12, 2012)
  4. Suri A (2012) Method of diagnosing cancer by detecting the expression of SPAG9 or the presence of anti-SPAG9 antibodies European Patent No. EP1796723 (Granted on November 14, 2012)
  5. Suri A Novel Cancer Associated Antibodies And Their Use In Cancer Diagnosis United States of America Patent No. US 20100221742 A1 (Publication September 2, 2010)
  6. Suri A (2012) Novel Cancer Associated antibodies & antigens and their use in cancer diagnosis. Country: Australia Patent No. AU2005290997 (Filed on April 4, 2007 Granted on Dec 20, 2012)
  7. Suri A (2012) Novel Cancer Associated antibodies & antigens and their use in cancer diagnosis. Country: United Kingdom UK Patent No.UK 1796723 (Filed on Sept 24, 2012 Granted on Oct 12, 2012)
  8. Suri A (2012) Novel Cancer Associated antibodies & antigens and their use in cancer diagnosis. Country: Singapore Patent No. 156619 (Filed on Oct 7, 2009 Granted on July 13, 2012)
  9. Suri A Inhibition of SPAG9 expression with siRNAs, Country: Australia Patent No: 2006219666 (Granted on May 12, 2011)
  10. Suri A Novel Nucleotide Sequences, Country: Singapore Patent No: 135339 (Granted on June 15, 2010)
  11. Suri A Inhibition of SPAG9 expression with siRNAs.Country:Singapore Patent No: SG135339 (Granted on June 15, 2010)
  12. Suri A Inhibition of SPAG9 expression with siRNAs Country: Europe (Validated in Germany, France, Finland, UK, Italy, Sweden, Switzerland) Patent No: EP1861496 (Granted on September 16, 2009)

Awards & Fellowships

  1. Gold Medal-Dr. T.C. Anand Kumar Memorial Oration Award-2015 conferred by ISSRF for Reproductive tract cancers.
  2. Citation Award for 6th Professor Rabindra Nath Chakravarti-2014 conferred by Post Graduate Institute of Medical Education and Research, Chandigarh in recognition of outstanding contribution in the field of Cancer Research.
  3. Prof. L.S. Ramaswami Memorial Oration Award-2013 conferred by ISSRF in recognition of research contribution in Reproductive tract cancers.
  4. Drs Anand and Lata “Labhsetwar Charitable Trust, Labhsetwar Foundation” USA Award-2011 conferred by ISSRF in recognition of outstanding contribution in the field of Reproductive Health: Cervical Cancer.
  5. Young Investigator Award of Department of Biotechnology, 1990.
  6. Best Research leading to Product award in 1988 of National Institute of Immunology, Department of Biotechnology, New Delhi, India.
  7. Elected Fellow, National Academy of Medical Sciences (FAMS), India (2013).
  8. Elected Fellow, The National Academy of Sciences (FNASc), India (2009).
  9. Elected Executive Member, Indian Association of Cancer Research (IACR), India (2016).
  10. Vice President, ISSRF, India (2016).

Cervix Cancer

  • Small interfering RNA-mediated down regulation of Sperm-Associated Antigen 9 inhibits cervix tumor growth. Garg M, Kanojia D, Suri S, and Suri A. Cancer (journal). 2009. PMID 19813278
  • Sperm-Associated Antigen 9 (SPAG9) is a biomarker for early cervical carcinoma. Garg M, Kanojia D, Salhan S, Suri S, Gupta A, Lohiya NK, and Suri A. Cancer (journal). 2009. PMID 19326449
  • Germ cell specific Heat shock protein 70-2 is expressed in cervical carcinoma and is involved in growth, migration and invasion of cervix cells. Garg M, D. Kanojia D, S. Saini S, S. Suri S, A. Gupta A, A. Surolia A, and A. Suri A. Cancer (journal). 2010. PMID 20564126
  • Gene silencing of A-kinase anchor protein 4 inhibits cervical cancer growth in vitro and in vivo. Saini S, Agarwal S, Sinha A, Verma A, Parashar D, Gupta N, Ansari AS, Lohiya NK, Jagadish N, Suri A. Cancer Gene Ther. 2013. PMID 23764900

    • Breast Cancer

  • Sperm Associated Antigen 9 (SPAG9), a novel biomarker for early detection of Breast Cancer. Kanojia D, Garg M, Gupta S, Gupta A, and Suri A. Cancer Epidemiology, Biomarkers & Prevention. 2009. PMID 19190149
  • A novel cancer testis antigen, A-kinase anchor protein 4 (AKAP4) is a potential biomarker for breast cancer. Saini S, Jagadish N, Gupta A, Bhatnagar A, Suri A. PLOS ONE. 2013 PMID 23451156

    • Ovarian Cancer

  • Sperm Associated Antigen 9 (SPAG9), a novel Cancer testis antigen is potential target for Immunotherapy in epithelial ovarian cancer. Garg M, Chaurasiya D, Rana R, Jagadish N, Kanojia D, Dudha N, Kamran N, Salhan S, Bhatnagar A, Suri S, Gupta A and Suri A. Clinical Cancer Research. 2007. PMID 17332284
  • A novel cancer testis antigen, A-kinase anchor protein 4 (AKAP4) is a putative target for immunotherapy of ovarian serous carcinoma. Agarwal S, Saini S, Parashar D, Verma A, Sinha A, Jagadish N, Gupta A, Batra A, Suri S, Bhatnagar A, Ansari AS, Lohiya NK and Suri A. Oncoimmunology. 2013. PMID 23762804

    • Renal Cell Carcinoma

  • Sperm Associated Antigen 9 is associated with tumor growth, migration and invasion in Renal cell carcinoma. Garg M, Kanojia D, Khosla A, Dudha N, Sati S, Chaurasiya D, Jagadish N, Seth A, Kumar R, Gupta S, Gupta A, K. Lohiya NK and Suri A. Cancer Research (journal) 2008. PMID 18922895

    • Colorectal Carcinoma

  • Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Kanojia D, Garg M, Gupta S, Gupta A, Suri A. American Journal of Pathology. 2011. PMID 21356354
  • A novel cancer testis antigen target A-Kinase Anchor Protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer. Jagadish N, Parashar D, Gupta N, Agarwa S, Sharma A, Fatima R, Suri V, Kumar R, Gupta A, Lohiya NK, and Suri A. OncoImmunology. 2016. PMID 27057472
  • A-kinase anchor protein 4 (AKAP4) a promising therapeutic target of colorectal cancer. Jagadish N, Parashar D, Gupta N, Agarwal S, Purohit S, Kumar V, Sharma A, Fatima R, Topno AP, Shaha C, Suri A. J Exp Clin Cancer Res. 2015. PMID 26590805

    • Salivary gland cancer

  • Sperm Associated Antigen 9 (SPAG9) expressions and humoral response in benign and malignant salivary gland tumors. Agarwal S, Parashar D, Gupta N, Jagadish N, Thakar A, Suri V, Kumar R, Gupta A, Ansari AS, Lohiya NK, and Suri A. Oncoimmunology, 2014. PMID 25941602

    • Thyroid Cancer

  • Sperm-Associated Antigen 9, a novel diagnostic marker for Thyroid Cancer. Garg M, Kanojia D, Suri S, Gupta S, Gupta A and Suri A. Journal of Clinical Endocrinology & Metabolism. 2009. PMID 19820019

    • Chronic myeloid leukemia

  • Sperm Associated Antigen 9 expression and humoral response in Chronic Myeloid Leukemia. Kanojia D, Garg M, Saini S, Agarwal S, Kumar R, Suri A. Leukemia Research. 2010. PMID 20138665

    • References

    Anil Suri Wikipedia
    (Text) CC BY-SA